Pub Date : 2010-09-01DOI: 10.1097/TEN.0B013E3181F64E6D
Ş. Erdeve, E. Şimşek, Y. Dallar, Z. Bıyıklı
Abstract: We evaluated familial aggregation of metabolic syndrome components in obese children. A total of 198 obese children and their parents were enrolled in a prospective cohort study and were evaluated for the intrafamilial relationships of metabolic syndrome components. Metabolic syndrome was diagnosed in 25 (26%) of 96 obese boys, in 27 (26.4%) of 102 obese girls, in 53 (34.8%) of 152 mothers, and in 37 (33.6%) of 110 fathers. Compared with obese boys, obese girls showed higher correlations with their mothers for waist circumference, systolic blood pressure, and high-density lipoprotein cholesterol and with their fathers for total cholesterol. Compared with obese girls, obese boys showed higher correlations with their fathers for waist circumference, body mass index, high-density lipoprotein cholesterol, triglyceride, fasting plasma glucose, and diastolic blood pressure and with their mothers for total cholesterol, low-density lipoprotein, and triglyceride. There was a significant resemblance of metabolic syndrome and its components among families. Gender-related correlations should be considered for future interventions.
{"title":"Familial Clustering of Metabolic Syndrome Components in Parents of Obese Children","authors":"Ş. Erdeve, E. Şimşek, Y. Dallar, Z. Bıyıklı","doi":"10.1097/TEN.0B013E3181F64E6D","DOIUrl":"https://doi.org/10.1097/TEN.0B013E3181F64E6D","url":null,"abstract":"Abstract: We evaluated familial aggregation of metabolic syndrome components in obese children. A total of 198 obese children and their parents were enrolled in a prospective cohort study and were evaluated for the intrafamilial relationships of metabolic syndrome components. Metabolic syndrome was diagnosed in 25 (26%) of 96 obese boys, in 27 (26.4%) of 102 obese girls, in 53 (34.8%) of 152 mothers, and in 37 (33.6%) of 110 fathers. Compared with obese boys, obese girls showed higher correlations with their mothers for waist circumference, systolic blood pressure, and high-density lipoprotein cholesterol and with their fathers for total cholesterol. Compared with obese girls, obese boys showed higher correlations with their fathers for waist circumference, body mass index, high-density lipoprotein cholesterol, triglyceride, fasting plasma glucose, and diastolic blood pressure and with their mothers for total cholesterol, low-density lipoprotein, and triglyceride. There was a significant resemblance of metabolic syndrome and its components among families. Gender-related correlations should be considered for future interventions.","PeriodicalId":50531,"journal":{"name":"Endocrinologist","volume":"30 1","pages":"240-242"},"PeriodicalIF":0.0,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83411462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2010-09-01DOI: 10.1097/TEN.0B013E3181F6503F
P. Rosário, D. Salles, Breno Bessa, S. Purisch
We investigated the evolution of thyroid nodules ≤1 cm without suspicious ultrasonographic characteristics and hot nodules detected by 131I scintigraphy (that do not require cytologic evaluation) in patients who are at low risk for malignancy. A total of 148 patients with 290 nodules ≤1 cm without suspicious characteristics and 32 subjects with low thyroid stimulating hormone and 55 hot nodules were studied. Thirty-six of the 290 nodules ≤1 cm without suspicious characteristics exhibited growth during follow-up and were punctured. Cytology was interpreted as benign in 28 cases, insufficient in 6, indeterminate in 1, and suspicious of malignancy in another (papillary carcinoma). Ten patients with hot nodules were treated with radioiodine because of progression to hyperthyroidism. Twenty patients with 35 hot nodules were followed and none had significant nodule growth. Therefore, malignancy was observed in only 1 of 345 nodules (0.3%) without an initial indication for cytology. Cytology is not necessary in the case of nodules ≤1 cm that have no suspicious radiologic features or hot nodules in patients without a history of neck radiation during childhood or a family history of thyroid carcinoma.
{"title":"Nodular Thyroid Disease: Natural History of Nodules Without an Initial Indication for Cytology","authors":"P. Rosário, D. Salles, Breno Bessa, S. Purisch","doi":"10.1097/TEN.0B013E3181F6503F","DOIUrl":"https://doi.org/10.1097/TEN.0B013E3181F6503F","url":null,"abstract":"We investigated the evolution of thyroid nodules ≤1 cm without suspicious ultrasonographic characteristics and hot nodules detected by 131I scintigraphy (that do not require cytologic evaluation) in patients who are at low risk for malignancy. \u0000A total of 148 patients with 290 nodules ≤1 cm without suspicious characteristics and 32 subjects with low thyroid stimulating hormone and 55 hot nodules were studied. Thirty-six of the 290 nodules ≤1 cm without suspicious characteristics exhibited growth during follow-up and were punctured. Cytology was interpreted as benign in 28 cases, insufficient in 6, indeterminate in 1, and suspicious of malignancy in another (papillary carcinoma). Ten patients with hot nodules were treated with radioiodine because of progression to hyperthyroidism. Twenty patients with 35 hot nodules were followed and none had significant nodule growth. Therefore, malignancy was observed in only 1 of 345 nodules (0.3%) without an initial indication for cytology. \u0000Cytology is not necessary in the case of nodules ≤1 cm that have no suspicious radiologic features or hot nodules in patients without a history of neck radiation during childhood or a family history of thyroid carcinoma.","PeriodicalId":50531,"journal":{"name":"Endocrinologist","volume":"39 1","pages":"243-244"},"PeriodicalIF":0.0,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74814660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2010-09-01DOI: 10.1097/TEN.0B013E3181F661EC
C. Hsieh, Y. Hung, D. Pei, Chung-Ze Wu, Fone-Ching Hsiao
Abstract: Retinol-binding protein-4 (RBP4) is a novel adipokine, which is reported to be associated with obesity and insulin resistance (IR). We studied the effect of rosiglitazone (ROS), an insulin sensitizer, on the RBP4 plasma concentrations in subjects with impaired glucose tolerance (IGT). A single-blind, placebo-controlled comparison trial was conducted. A total of 26 IGT patients (mean age of 54 years) were enrolled; 14 received ROS (4 mg daily) and 12 received placebo. An enzyme immunoassay (EIA) was used to measure plasma RBP4 concentrations before and after therapy in both treatment groups. Plasma RBP4 concentrations were not associated with IR and cardiovascular risk factors with the exception of serum creatine levels. ROS therapy decreased RBP4 levels independent of IR, but associated with the changes in aspartate aminotransferase and triglyceride levels as well as basal serum RBB4 concentrations. In brief, plasma RBP4 concentrations in IGT subjects did not correlate with most cardiovascular risk factors and IR. However, treating IGT subjects with ROS resulted in decreased RBP4 levels independent of IR.
{"title":"The effect of rosiglitazone on retinol binding protein 4 in subjects of impaired glucose tolerance","authors":"C. Hsieh, Y. Hung, D. Pei, Chung-Ze Wu, Fone-Ching Hsiao","doi":"10.1097/TEN.0B013E3181F661EC","DOIUrl":"https://doi.org/10.1097/TEN.0B013E3181F661EC","url":null,"abstract":"Abstract: Retinol-binding protein-4 (RBP4) is a novel adipokine, which is reported to be associated with obesity and insulin resistance (IR). We studied the effect of rosiglitazone (ROS), an insulin sensitizer, on the RBP4 plasma concentrations in subjects with impaired glucose tolerance (IGT). A single-blind, placebo-controlled comparison trial was conducted. A total of 26 IGT patients (mean age of 54 years) were enrolled; 14 received ROS (4 mg daily) and 12 received placebo. An enzyme immunoassay (EIA) was used to measure plasma RBP4 concentrations before and after therapy in both treatment groups. Plasma RBP4 concentrations were not associated with IR and cardiovascular risk factors with the exception of serum creatine levels. ROS therapy decreased RBP4 levels independent of IR, but associated with the changes in aspartate aminotransferase and triglyceride levels as well as basal serum RBB4 concentrations. In brief, plasma RBP4 concentrations in IGT subjects did not correlate with most cardiovascular risk factors and IR. However, treating IGT subjects with ROS resulted in decreased RBP4 levels independent of IR.","PeriodicalId":50531,"journal":{"name":"Endocrinologist","volume":"2 1","pages":"250-253"},"PeriodicalIF":0.0,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88776941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2010-09-01DOI: 10.1097/TEN.0B013E3181F47FB2
Peggy Nelson, V. Gossain
Objective: To describe a case where continuous use of antithyroid medications was safely and effectively employed for the treatment of hyperthyroidism over a period of 14 years in a patient who refused radioactive ablative therapy and surgery. Case Report: The patient is a 71-year-old woman who presented with complaints of tachycardia and tremors along with a diffusely enlarged goiter without appreciable nodules. At the time of evaluation, she was clinically and biochemically hyperthyroid. An I123 thyroid uptake and scan revealed a toxic multinodular goiter. She was started on propylthiouracil therapy, which was discontinued due to generalized pruritus. After approximately 4 months of refusing alternative antithyroid therapy, she was started on methimazole. In the subsequent 14 years of management, she relapsed 3 times off antithyroid drugs. However, she never developed any major side effects with the maintenance of methimazole dose of 5 mg daily. Conclusions: The goal of treatment for hyperthyroidism is to render the patient euthyroid safely. However, when treated with radioactive ablative therapy or surgery, the patient is at high risk of being on lifelong thyroxine therapy. Therefore, it appears reasonable that well-informed patients who would prefer lifelong antithyroid therapy, as opposed to lifelong thyroxine therapy, should be given that option.
{"title":"Prolonged Treatment With Antithyroid Drugs: How Long to Treat Safely … Months, Years, or a Lifetime?","authors":"Peggy Nelson, V. Gossain","doi":"10.1097/TEN.0B013E3181F47FB2","DOIUrl":"https://doi.org/10.1097/TEN.0B013E3181F47FB2","url":null,"abstract":"Objective: To describe a case where continuous use of antithyroid medications was safely and effectively employed for the treatment of hyperthyroidism over a period of 14 years in a patient who refused radioactive ablative therapy and surgery. Case Report: The patient is a 71-year-old woman who presented with complaints of tachycardia and tremors along with a diffusely enlarged goiter without appreciable nodules. At the time of evaluation, she was clinically and biochemically hyperthyroid. An I123 thyroid uptake and scan revealed a toxic multinodular goiter. She was started on propylthiouracil therapy, which was discontinued due to generalized pruritus. After approximately 4 months of refusing alternative antithyroid therapy, she was started on methimazole. In the subsequent 14 years of management, she relapsed 3 times off antithyroid drugs. However, she never developed any major side effects with the maintenance of methimazole dose of 5 mg daily. Conclusions: The goal of treatment for hyperthyroidism is to render the patient euthyroid safely. However, when treated with radioactive ablative therapy or surgery, the patient is at high risk of being on lifelong thyroxine therapy. Therefore, it appears reasonable that well-informed patients who would prefer lifelong antithyroid therapy, as opposed to lifelong thyroxine therapy, should be given that option.","PeriodicalId":50531,"journal":{"name":"Endocrinologist","volume":"1 1","pages":"217-219"},"PeriodicalIF":0.0,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88326811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2010-09-01DOI: 10.1097/TEN.0B013E3181F47CE8
H. Rehman, Claire E. Michaels
Abstract: A case of disordered calcium metabolism is presented in which the patient had several presentations with hyper- or hypocalcemia.
摘要:钙代谢紊乱的情况下，提出了病人有几个表现与高或低钙血症。
{"title":"Hyper- and Hypocalcemia: Pitfalls in Interpretation and Treatment","authors":"H. Rehman, Claire E. Michaels","doi":"10.1097/TEN.0B013E3181F47CE8","DOIUrl":"https://doi.org/10.1097/TEN.0B013E3181F47CE8","url":null,"abstract":"Abstract: A case of disordered calcium metabolism is presented in which the patient had several presentations with hyper- or hypocalcemia.","PeriodicalId":50531,"journal":{"name":"Endocrinologist","volume":"1 1","pages":"226-227"},"PeriodicalIF":0.0,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88124100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2010-09-01DOI: 10.1097/TEN.0B013E3181F661D2
E. Schmidtová, S. Kelemenova, P. Celec, A. Ficek, D. Ostatníková
Autism spectrum disorders (ASDs) are neurodevelopment disorders which are characterized by impairments in the following core domains: social interaction, language development, verbal/nonverbal communication, and repetitive and restricted behaviors. The androgen theory of autism proposes that autism spectrum disorders develop in part due to elevated fetal testosterone levels, which correlate with a number of autistic traits. The present study evaluates androgen and estrogen levels in saliva as well as polymorphisms in genes for androgen receptor (AR), 5-alpha reductase (SRD5A2), and estrogen receptor alpha (ESR1) in the Slovak population of prepubertal (under 10 years) and pubertal (over 10 years) children with autism spectrum disorders. The examined prepubertal patients with autism, pubertal patients with autism, and prepubertal patients with Asperger syndrome had significantly increased levels of salivary testosterone (P 0.05, P 0.01, and P 0.05, respectively) in comparison with control subjects. We found a lower number of (CAG)n repeats in the AR gene in boys with Asperger syndrome (P 0.001). Autistic boys had an increased frequency of the T allele in the SRD5A2 gene in comparison with the control group. The frequencies of T and C alleles in ESR1 gene were comparable in all assessed groups. The modulating influence of studying genotypes on the effect of testosterone could provide insight into the pathogenesis of autism spectrum disorders.
自闭症谱系障碍(ASDs)是一种神经发育障碍，其特征是在以下核心领域受损:社会互动、语言发展、语言/非语言交流、重复和限制性行为。自闭症的雄激素理论提出，自闭症谱系障碍的发展部分是由于胎儿睾酮水平升高，这与许多自闭症特征相关。本研究评估了斯洛伐克青春期前(10岁以下)和青春期(10岁以上)自闭症谱系障碍儿童唾液中的雄激素和雌激素水平，以及雄激素受体(AR)、5- α还原酶(SRD5A2)和雌激素受体α (ESR1)基因多态性。被检查的青春期前孤独症患者、青春期前孤独症患者和青春期前阿斯伯格综合征患者的唾液睾酮水平均显著高于对照组(P < 0.05, P < 0.01, P < 0.05)。我们发现阿斯伯格综合症男孩的AR基因(CAG)n重复数较低(P < 0.001)。与对照组相比，自闭症男孩的SRD5A2基因中T等位基因的频率增加。ESR1基因中T和C等位基因的频率在所有评估组中具有可比性。研究基因型对睾酮作用的调节作用可以为自闭症谱系障碍的发病机制提供新的认识。
{"title":"Polymorphisms in Genes Involved in Testosterone Metabolism in Slovak Autistic Boys","authors":"E. Schmidtová, S. Kelemenova, P. Celec, A. Ficek, D. Ostatníková","doi":"10.1097/TEN.0B013E3181F661D2","DOIUrl":"https://doi.org/10.1097/TEN.0B013E3181F661D2","url":null,"abstract":"Autism spectrum disorders (ASDs) are neurodevelopment disorders which are characterized by impairments in the following core domains: social interaction, language development, verbal/nonverbal communication, and repetitive and restricted behaviors. The androgen theory of autism proposes that autism spectrum disorders develop in part due to elevated fetal testosterone levels, which correlate with a number of autistic traits. The present study evaluates androgen and estrogen levels in saliva as well as polymorphisms in genes for androgen receptor (AR), 5-alpha reductase (SRD5A2), and estrogen receptor alpha (ESR1) in the Slovak population of prepubertal (under 10 years) and pubertal (over 10 years) children with autism spectrum disorders. The examined prepubertal patients with autism, pubertal patients with autism, and prepubertal patients with Asperger syndrome had significantly increased levels of salivary testosterone (P 0.05, P 0.01, and P 0.05, respectively) in comparison with control subjects. We found a lower number of (CAG)n repeats in the AR gene in boys with Asperger syndrome (P 0.001). Autistic boys had an increased frequency of the T allele in the SRD5A2 gene in comparison with the control group. The frequencies of T and C alleles in ESR1 gene were comparable in all assessed groups. The modulating influence of studying genotypes on the effect of testosterone could provide insight into the pathogenesis of autism spectrum disorders.","PeriodicalId":50531,"journal":{"name":"Endocrinologist","volume":"4 1","pages":"245-249"},"PeriodicalIF":0.0,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87424857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2010-09-01DOI: 10.1097/TEN.0B013E3181E94ABF
H. Padmanabhan
Abstract: Managing toxic multinodular goiter in elderly patients can be challenging as age, presence of chronic disease, polypharmacy, and poor medication compliance can limit the use of surgery and long-term antithyroid drugs. Treatment with 131I may not produce the best outcome in states of low radioiodine uptake. Recombinant human thyroid-stimulating hormone (rh-TSH, Thyrogen) used as pretreatment for radioiodine therapy, however, can be useful in this clinical scenario. We report a patient successfully treated (a 94-year-old man on polypharmacy for multiple medical conditions) with radioiodine after pretreatment with rh-TSH. The radioiodine uptake increased with rh-TSH administration and allowed successful treatment with 15.4 mCu of 131I. Recovery from hyperthyroidism was associated with a 71% reduction in the size of thyroid gland by sonography.
{"title":"Radioiodine Therapy After Pretreatment With Recombinant Thyroid-stimulating Hormone (tsh) in Toxic Multinodular Goiter With Low Radioactive Iodine Uptake","authors":"H. Padmanabhan","doi":"10.1097/TEN.0B013E3181E94ABF","DOIUrl":"https://doi.org/10.1097/TEN.0B013E3181E94ABF","url":null,"abstract":"Abstract: Managing toxic multinodular goiter in elderly patients can be challenging as age, presence of chronic disease, polypharmacy, and poor medication compliance can limit the use of surgery and long-term antithyroid drugs. Treatment with 131I may not produce the best outcome in states of low radioiodine uptake. Recombinant human thyroid-stimulating hormone (rh-TSH, Thyrogen) used as pretreatment for radioiodine therapy, however, can be useful in this clinical scenario. We report a patient successfully treated (a 94-year-old man on polypharmacy for multiple medical conditions) with radioiodine after pretreatment with rh-TSH. The radioiodine uptake increased with rh-TSH administration and allowed successful treatment with 15.4 mCu of 131I. Recovery from hyperthyroidism was associated with a 71% reduction in the size of thyroid gland by sonography.","PeriodicalId":50531,"journal":{"name":"Endocrinologist","volume":"2 1","pages":"208-210"},"PeriodicalIF":0.0,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79247347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2010-09-01DOI: 10.1097/TEN.0B013E3181F64E80
A. Dʼantonio, A. Caleo, O. Caleo, F. Sessa, B. Angrisani
Abstract: We describe clinicopathologic features, laboratory data, and imaging and therapeutic management of a rare case of Hashimoto thyroiditis arising in struma ovarii. The patient was a 38-year-old woman with clinical symptoms of hyperthyroidism. Laboratory data showed elevated levels of total and free thyroxine, low thyrotropin level, and positive specific antithyroid antibodies without ultrasound evidence of morphologic abnormalities of the thyroid gland. Pelvic ultrasonography and magnetic resonance imaging of the abdomen showed bilateral solid ovarian masses containing cystic and fat areas diagnostic of teratoma. The performance of a 131I whole-body scan demonstrated a focus of intense uptake in the pelvis with minimal residual thyroid gland. The patient had a bilateral oophorectomy, and histologic examination revealed thyroid tissue in both masses with all the features of Hashimoto thyroiditis in the right ovary. Symptoms of hyperthyroidism diminished after the surgery, and the thyroid hormone levels and antithyroid antibodies were in the normal range in 1 month. The present case further confirms the rare occurrence of Hashimoto thyroiditis in struma ovarii. This diagnosis should be suggested in the differential diagnosis of patients with symptoms of thyroid disease and a normal thyroid gland.
{"title":"Hashimoto Thyroiditis as a Manifestation of Struma Ovarii","authors":"A. Dʼantonio, A. Caleo, O. Caleo, F. Sessa, B. Angrisani","doi":"10.1097/TEN.0B013E3181F64E80","DOIUrl":"https://doi.org/10.1097/TEN.0B013E3181F64E80","url":null,"abstract":"Abstract: We describe clinicopathologic features, laboratory data, and imaging and therapeutic management of a rare case of Hashimoto thyroiditis arising in struma ovarii. The patient was a 38-year-old woman with clinical symptoms of hyperthyroidism. Laboratory data showed elevated levels of total and free thyroxine, low thyrotropin level, and positive specific antithyroid antibodies without ultrasound evidence of morphologic abnormalities of the thyroid gland. Pelvic ultrasonography and magnetic resonance imaging of the abdomen showed bilateral solid ovarian masses containing cystic and fat areas diagnostic of teratoma. The performance of a 131I whole-body scan demonstrated a focus of intense uptake in the pelvis with minimal residual thyroid gland. The patient had a bilateral oophorectomy, and histologic examination revealed thyroid tissue in both masses with all the features of Hashimoto thyroiditis in the right ovary. Symptoms of hyperthyroidism diminished after the surgery, and the thyroid hormone levels and antithyroid antibodies were in the normal range in 1 month. The present case further confirms the rare occurrence of Hashimoto thyroiditis in struma ovarii. This diagnosis should be suggested in the differential diagnosis of patients with symptoms of thyroid disease and a normal thyroid gland.","PeriodicalId":50531,"journal":{"name":"Endocrinologist","volume":"118 1","pages":"220-221"},"PeriodicalIF":0.0,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73748416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2010-09-01DOI: 10.1097/TEN.0B013E3181F64C7A
H. Rehman
{"title":"Vitamin D Deficiency and Primary Hyperparathyroidism","authors":"H. Rehman","doi":"10.1097/TEN.0B013E3181F64C7A","DOIUrl":"https://doi.org/10.1097/TEN.0B013E3181F64C7A","url":null,"abstract":"","PeriodicalId":50531,"journal":{"name":"Endocrinologist","volume":"7 1","pages":"230-231"},"PeriodicalIF":0.0,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87096656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2010-09-01DOI: 10.1097/TEN.0B013E3181F660E9
A. Ulasli, M. Saraçoğlu, H. Genç, H. Erdem
{"title":"Celiac Disease Presenting With Low Back Pain: Do Not Forget Osteomalacia","authors":"A. Ulasli, M. Saraçoğlu, H. Genç, H. Erdem","doi":"10.1097/TEN.0B013E3181F660E9","DOIUrl":"https://doi.org/10.1097/TEN.0B013E3181F660E9","url":null,"abstract":"","PeriodicalId":50531,"journal":{"name":"Endocrinologist","volume":"44 1","pages":"222-223"},"PeriodicalIF":0.0,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77897119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：